Immutep (NASDAQ:IMMP) Stock Crosses Above Fifty Day Moving Average of $2.25

Immutep Limited (NASDAQ:IMMP)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.25 and traded as high as $2.34. Immutep shares last traded at $2.21, with a volume of 111,050 shares traded.

Analysts Set New Price Targets

Separately, Robert W. Baird lowered their target price on shares of Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, June 27th.

Immutep Trading Down 2.2 %

The business has a 50-day moving average price of $2.26 and a two-hundred day moving average price of $2.45.

Institutional Investors Weigh In On Immutep

Several institutional investors and hedge funds have recently bought and sold shares of IMMP. XTX Topco Ltd bought a new position in Immutep in the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets increased its stake in Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 4,700 shares during the last quarter. XY Capital Ltd acquired a new position in Immutep during the second quarter valued at approximately $105,000. Virtu Financial LLC lifted its stake in Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the last quarter. Finally, Oracle Investment Management Inc. boosted its holdings in shares of Immutep by 9.4% in the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after purchasing an additional 48,449 shares in the last quarter. Institutional investors own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.